Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genetic code

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Genetic code. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-004625-96 Sponsor Protocol Number: Protocol date 15. 9. 2004 Start Date*: 2005-10-21
    Sponsor Name:Group for the Study of Resistant Depression (GSRD), Head: Prof. Julien Mendlewicz
    Full Title: A naturalistic study of the efficacy and safety of escitalopram in treatment resistant depression.
    Medical condition: The screening assessment consists of a consecutive recruitment of depressed pat. adequately treated for their current depressive episode. 2. Pat. who failed to respond to a well-conducted treatment...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003665-10 Sponsor Protocol Number: RBH2017/001 Start Date*: 2020-02-25
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-003421-17 Sponsor Protocol Number: CL3-20098-051 Start Date*: 2009-02-18
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10018075 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003227-20 Sponsor Protocol Number: ZD4054 Start Date*: 2007-09-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free...
    Medical condition: hormone-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) NL (Completed) FR (Completed) PT (Completed) DK (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001899-11 Sponsor Protocol Number: C1701-202 Start Date*: 2019-11-07
    Sponsor Name:Cyclerion Therapeutics, Inc.
    Full Title: A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease
    Medical condition: Stable Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000256-35 Sponsor Protocol Number: CNPOBC2020 Start Date*: 2020-12-16
    Sponsor Name:Aalborg University Hospital
    Full Title: Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomised, double-blind, placebo-controlled trial
    Medical condition: Recurrent pregnancy loss after assisted reproductive technology treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10078356 Recurrent pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011115-20 Sponsor Protocol Number: NordLOTS protocol step 3 1.1 Start Date*: 2009-08-14
    Sponsor Name:The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)
    Full Title: Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the "Expert Clinical Guidelines". The study is performed with no sponsor from phar...
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049596 Obsession LLT
    9.1 10010219 Compulsions LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) NO (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005064-15 Sponsor Protocol Number: M14DPD Start Date*: 2015-02-12
    Sponsor Name:Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-ALV)
    Full Title: Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines
    Medical condition: Types of cancer for which capecitabine and 5-fluorouracil are authorized, this includes colorectal cancer, gastric cancer and locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002736-10 Sponsor Protocol Number: MVPV1 Start Date*: 2006-01-20
    Sponsor Name:Royal Marsden Hospital
    Full Title: Open, Randomised Phase II Study Assessing The Toxicity And Efficacy Of Platinum-Based Chemotherapy With Vitamin Supplementation In The Treatment Of Lung Cancer
    Medical condition: Non-small cell lung cancer Small-cell lung cancer Malignant Mesothelioma (ICD classification code:C45.9)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001340-21 Sponsor Protocol Number: KB046 Start Date*: 2013-01-15
    Sponsor Name:KEDRION
    Full Title: A Historically-Controlled Phase II/III study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed with Ligneous Conjunctivitis
    Medical condition: Ligneous Conjunctivitis ( MedDRA Code vers. 15.0: 10071570 LLT - no present in OsSC database) associated with Type I Plasminogen Deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020185-19 Sponsor Protocol Number: KP7242114 Start Date*: 2011-05-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Optimization of Treatment and Management of Schizophrenia in Europe
    Medical condition: Schizophrenia ICD-10 code F20 or schizophreniform disorder ICD-10 code F23.1
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) DK (Prematurely Ended) AT (Completed) BE (Completed) IT (Completed) BG (Completed) RO (Suspended by CA)
    Trial results: View results
    EudraCT Number: 2006-007018-39 Sponsor Protocol Number: Persephone Start Date*: 2007-08-09
    Sponsor Name:Cambridge Hospitals NHS Foundation Trust and Cambridge University
    Full Title: Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve
    Medical condition: HER2 positive early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006044-22 Sponsor Protocol Number: HGT-ELA-038 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire HGT)
    Full Title: A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy
    Medical condition: Mucopolysaccharidosis Type II (MPS II or Hunter Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    10.1 10056889 PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000079-38 Sponsor Protocol Number: DB-OTO-001 Start Date*: 2023-05-09
    Sponsor Name:Decibel Therapeutics
    Full Title: A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tol...
    Medical condition: Congenital auditory neuropathy secondary to biallelic mutations of the otoferlin gene (hOTOF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10011874 Deaf LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003787-24 Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 Start Date*: 2023-04-20
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety...
    Medical condition: Unresectable intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003422-32 Sponsor Protocol Number: AMoRe2017 Start Date*: 2018-04-25
    Sponsor Name:Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) gGmbH
    Full Title: INTERNATIONAL MULTICENTER, OPEN-LABEL, PHASE 2 STUDY TO TREAT MOLECULAR RELAPSE OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH AZACITIDINE
    Medical condition: Intravenous azacitidine 100 mg/m2, Days 1 to 7 of a 28-day cycle for up to 3 cycles initially. In case of decline of MRD during azacitidine treatment additional cycles are allowed (maximum 6 cycl...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Prematurely Ended) SE (Completed) BE (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005377-29 Sponsor Protocol Number: CNS 2004 03 Start Date*: 2006-05-03
    Sponsor Name:Dept of Pediatrics, University Hospital of North Norway
    Full Title: SIOP-LGG 2004 Cooperative multicenter Study for Children and Adolescents with Low Grade Gliome
    Medical condition: Low Grade Glioma
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Ongoing) IE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005629-65 Sponsor Protocol Number: RG_12-269 Start Date*: 2014-01-15
    Sponsor Name:University of Birmingham
    Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study
    Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000062-24 Sponsor Protocol Number: D0810C00021 Start Date*: 2008-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: Ensayo fase I/II, abierto, multicéntrico, de AZD2281 oral en combinación con Cisplatino, para valorar la seguridad y tolerabilidad en pacientes con tumores sólidos avanzados, y para valorar la efic...
    Medical condition: Tumores sólidos avanzados, cáncer de mama triple negativo Advanced Solid Tumours, Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003605-26 Sponsor Protocol Number: PRO044-CLIN-02 Start Date*: 2014-12-02
    Sponsor Name:Prosensa Therapeutics B.V.
    Full Title: A phase II, open label, extension study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed) SE (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 00:02:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA